{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:01:00Z","timestamp":1781013660796,"version":"3.54.1"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research (CIHR)","doi-asserted-by":"publisher","award":["MOP-311262"],"award-info":[{"award-number":["MOP-311262"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease mainly characterized by the hyperproliferation and abnormal differentiation of the epidermal keratinocytes. An interesting phenolic compound, namely quebecol (2,3,3-tri-(3-methoxy-4-hydroxyphenyl)-1-propanol) (compound 1, CPD1), was isolated from maple syrup in 2011 and was recently synthesized. Quebecol and its derivatives ethyl 2,3,3-tris(3-hydroxy-4-methoxyphenyl)propenoate (compound 2, CPD2) and bis(4-hydroxy-3-methoxyphenyl)methane (compound 3, CPD3) have shown antiproliferative and anti-inflammatory potential, making them promising candidates for the treatment of psoriasis. This study aimed to evaluate the antipsoriatic potential of quebecol and its derivatives on psoriatic skin substitutes produced according to the self-assembly method. A sulforhodamine B (SRB) assay determining the concentration that inhibits 20% of cell growth (IC20) was performed for CPD1, CPD2 and CPD3, and their IC20 values were 400, 150 and 350 \u03bcM, respectively. At these concentrations, cell viability was 97%, 94% and 97%, respectively. The comparative control methotrexate (MTX) had a cell viability of 85% at a concentration of 734 \u03bcM. Histological analyses of psoriatic skin substitutes treated with CPD1, CPD2 and CPD3 exhibited significantly reduced epidermal thickness compared with untreated psoriatic substitutes, which agreed with a decrease in keratinocyte proliferation as shown by Ki67 immunofluorescence staining. The immunofluorescence staining of differentiation markers (keratin 14, involucrin and loricrin) showed improved epidermal differentiation. Taken together, these results highlight the promising potential of quebecol and its derivatives for the treatment of psoriasis.<\/jats:p>","DOI":"10.3390\/pharmaceutics14061129","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T23:43:03Z","timestamp":1653867783000},"page":"1129","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antipsoriatic Potential of Quebecol and Its Derivatives"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-1018","authenticated-orcid":false,"given":"Corinne","family":"Bouchard","sequence":"first","affiliation":[{"name":"Centre de Recherche en Organog\u00e9n\u00e8se Exp\u00e9rimentale de L\u2019Universit\u00e9 Laval\/LOEX, Axe M\u00e9decine R\u00e9g\u00e9n\u00e9ratrice, Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec, QC GIJ 1Z4, Canada"},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval, Quebec, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-4968","authenticated-orcid":false,"given":"Alexe","family":"Grenier","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Organog\u00e9n\u00e8se Exp\u00e9rimentale de L\u2019Universit\u00e9 Laval\/LOEX, Axe M\u00e9decine R\u00e9g\u00e9n\u00e9ratrice, Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec, QC GIJ 1Z4, Canada"},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval, Quebec, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-2691","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Cardinal","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Biologie, Chimie et G\u00e9ographie, Universit\u00e9 du Qu\u00e9bec \u00e0 Rimouski, Rimouski, QC G5L 3A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"B\u00e9langer","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Organog\u00e9n\u00e8se Exp\u00e9rimentale de L\u2019Universit\u00e9 Laval\/LOEX, Axe M\u00e9decine R\u00e9g\u00e9n\u00e9ratrice, Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec, QC GIJ 1Z4, Canada"},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval, Quebec, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Voyer","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Chimie and PROTEO, Facult\u00e9 des Sciences et G\u00e9nie, Universit\u00e9 Laval, Quebec, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Pouliot","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Organog\u00e9n\u00e8se Exp\u00e9rimentale de L\u2019Universit\u00e9 Laval\/LOEX, Axe M\u00e9decine R\u00e9g\u00e9n\u00e9ratrice, Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec, QC GIJ 1Z4, Canada"},{"name":"Facult\u00e9 de Pharmacie, Universit\u00e9 Laval, Quebec, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1468-3083.2001.00192.x","article-title":"The prevalence of psoriasis in the world","volume":"15","author":"Raychaudhuri","year":"2001","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.18203\/2320-6012.ijrms20161733","article-title":"Histopathologic diagnostic parameters of psoriasis; a clinicopathological study","volume":"4","author":"Bai","year":"2016","journal-title":"Int. J. Res. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Camisa, C. (2004). Pathogenesis of Psoriasis. Handbook of Psoriasis, Blackwell Publishing. [2nd ed.].","DOI":"10.1002\/9780470750704"},{"key":"ref_4","unstructured":"Eroschenko, V.P. (2008). DiFiore\u2019s Atlas of Histology with Functional Correlations, Lippincott Williams & Wilkins. [11th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jdv.15252","article-title":"Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: Results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)","volume":"33","author":"Tveit","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/jmf.2009.0029","article-title":"Antioxidant Activity, Inhibition of Nitric Oxide Overproduction, and In Vitro Antiproliferative Effect of Maple Sap and Syrup from Acer saccharum","volume":"13","author":"Legault","year":"2010","journal-title":"J. Med. Food"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.foodchem.2005.05.079","article-title":"Antioxidant, antiradical and antimutagenic activities of phenolic compounds present in maple products","volume":"98","author":"Caillet","year":"2006","journal-title":"Food Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jff.2013.09.026","article-title":"Phenolic mediated anti-inflammatory properties of a maple syrup extract in RAW 264.7 murine macrophages","volume":"6","author":"Nahar","year":"2014","journal-title":"J. Funct. Foods"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jff.2011.10.004","article-title":"Anticancer effects of maple syrup phenolics and extracts on proliferation, apoptosis, and cell cycle arrest of human colon cells","volume":"4","author":"Li","year":"2012","journal-title":"J. Funct. Foods"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jff.2011.02.004","article-title":"Quebecol, a novel phenolic compound isolated from Canadian maple syrup","volume":"3","author":"Li","year":"2011","journal-title":"J. Funct. Foods"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.tetlet.2013.07.048","article-title":"Total synthesis of quebecol","volume":"54","author":"Cardinal","year":"2013","journal-title":"Tetrahedron Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1016\/j.bmcl.2013.07.058","article-title":"Synthesis and antiproliferative activities of quebecol and its analogs","volume":"23","author":"Pericherla","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bmcl.2015.11.096","article-title":"Anti-inflammatory properties of quebecol and its derivatives","volume":"26","author":"Cardinal","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.bmc.2017.01.050","article-title":"Synthesis and anti-inflammatory activity of isoquebecol","volume":"25","author":"Cardinal","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_16","first-page":"392","article-title":"The possibilities and principles of methotrexate treatment of psoriasis\u2014The updated knowledge","volume":"31","year":"2014","journal-title":"Postepy. Dermatol. Alergol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2340\/00015555-2081","article-title":"Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation","volume":"96","author":"Menting","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"B\u00e9langer, A., Grenier, A., Simard, F., Gendreau, I., Pichette, A., Legault, J., and Pouliot, R. (2019). Dihydrochalcone Derivatives from Populus balsamifera L. Buds for the Treatment of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010256"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0305-4179(93)90028-7","article-title":"Improvement of human keratinocyte isolation and culture using thermolysin","volume":"19","author":"Germain","year":"1993","journal-title":"Burns"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF02634255","article-title":"Skin equivalent produced with human collagen","volume":"31","author":"Auger","year":"1995","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_22","unstructured":"Maguire, T., and Novik, E. (2010). Markers for an in vitro skin substitute. Methods in Bioengineering: Alternative Technologies to Animal Testing, Artech House."},{"key":"ref_23","first-page":"001","article-title":"Bioengineered Skin: The Self- Assembly Approach","volume":"S5","author":"Jean","year":"2011","journal-title":"J. Tissue Sci. Eng."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jdermsci.2008.07.009","article-title":"Development of an in vitro psoriatic skin model by tissue engineering","volume":"53","author":"Jean","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1089\/ten.tea.2010.0463","article-title":"Effects of Retinoic Acid on Keratinocyte Proliferation and Differentiation in a Psoriatic Skin Model","volume":"17","author":"Jean","year":"2011","journal-title":"Tissue Eng. Part A"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/term.1666","article-title":"Characterization of a psoriatic skin model produced with involved or uninvolved cells","volume":"9","author":"Jean","year":"2015","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Morin, A., Simard, M., Rioux, G., Grenier, A., Morin, S., and Pouliot, R. (2019). Application of an In Vitro Psoriatic Skin Model to Study Cutaneous Metabolization of Tazarotene. Processes, 7.","DOI":"10.3390\/pr7120871"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.jid.2021.02.755","article-title":"Investigation of Omega-3 Polyunsaturated Fatty Acid Biological Activity in a Tissue-Engineered Skin Model Involving Psoriatic Cells","volume":"141","author":"Simard","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159032","DOI":"10.1016\/j.bbalip.2021.159032","article-title":"Biological action of docosahexaenoic acid in a 3D tissue-engineered psoriatic skin model: Focus on the PPAR signaling pathway","volume":"1866","author":"Morin","year":"2021","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Grenier, A., Legault, J., Pichette, A., Jean, L., B\u00e9langer, A., and Pouliot, R. (2021). Antioxidant, Anti-Inflammatory, and Anti-Aging Potential of a Kalmia angustifolia Extract and Identification of Some Major Compounds. Antioxidants, 10.","DOI":"10.3390\/antiox10091373"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/exd.13525","article-title":"Past, present and future of in vitro 3D reconstructed inflammatory skin models to study psoriasis","volume":"27","author":"Niehues","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jid.2016.11.022","article-title":"IL-6 Differs from TNF-\u03b1: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis","volume":"137","author":"Blauvelt","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-\u03b1) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.20031482","article-title":"Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-\u03b1","volume":"199","author":"Boyman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-008-0893-7","article-title":"TNF-\u03b1 production in the skin","volume":"301","author":"Bashir","year":"2009","journal-title":"Arch. Dermatol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1084\/jem.172.6.1609","article-title":"Human keratinocytes are a source for tumor necrosis factor alpha: Evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light","volume":"172","author":"Schwarz","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-\u03baB: An essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","article-title":"Differential Expression of Phosphorylated NF-\u03baB\/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-\u03baB in Response to Treatment with Etanercept","volume":"124","author":"Lizzul","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2007.05.024","article-title":"Crosstalk between Keratinocytes and Adaptive Immune Cells in an I\u03baB\u03b1 Protein-Mediated Inflammatory Disease of the Skin","volume":"27","author":"Rebholz","year":"2007","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/ijd.12050","article-title":"Role of NF-\u03baB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens","volume":"53","author":"Moorchung","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jep.2013.10.034","article-title":"Picea mariana polyphenolic extract inhibits phlogogenic mediators produced by TNF-\u03b1-activated psoriatic keratinocytes: Impact on NF-\u03baB pathway","volume":"151","author":"Allaeys","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Huang, T.-H., Lin, C.-F., Alalaiwe, A., Yang, S.-C., and Fang, J.-Y. (2019). Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102558"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00371784","article-title":"Normal psoriatic epidermis expression of hyperproliferation-associated keratins","volume":"283","author":"Thewes","year":"1991","journal-title":"Arch. Dermatol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0092-8674(79)90123-5","article-title":"Presence in human epidermal cells of a soluble protein precursor of the cross-linked envelope: Activation of the cross-linking by calcium ions","volume":"18","author":"Rice","year":"1979","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1074\/jbc.272.3.2021","article-title":"Direct Evidence That Involucrin Is a Major Early Isopeptide Cross-linked Component of the Keratinocyte Cornified Cell Envelope","volume":"272","author":"Steinert","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/1523-1747.ep12665870","article-title":"Differences in Involucrin Immunolabeling Within Cornified Cell Envelopes in Normal and Psoriatic Epidermis","volume":"104","author":"Iizuka","year":"1995","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/1047-8477(90)90071-J","article-title":"Biosynthetic pathways of filaggrin and loricrin\u2014two major proteins expressed by terminally differentiated epidermal keratinocytes","volume":"104","author":"Steven","year":"1990","journal-title":"J. Struct. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clindermatol.2007.08.005","article-title":"The histopathologic spectrum of psoriasis","volume":"25","author":"Murphy","year":"2007","journal-title":"Clin. Dermatol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/6\/1129\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:55Z","timestamp":1760138335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/6\/1129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["pharmaceutics14061129"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14061129","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}